Interventions to improve adherence and persistence with osteoporosis medications: A systematic literature review

Osteoporosis International

Volumn 20, Issue 12, 2009, Pages 2127-2134

  Gleeson, T ^a   Iversen, M D ^a,b   Avorn, J ^a   Brookhart, A M ^a   Katz, J N ^a   Losina, E ^a   May, F ^a   Patrick, A R ^a   Shrank, W H ^a   Solomon, D H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MGH INSTITUTE OF HEALTH PROFESSIONS   (United States)

Author keywords

Adherence; Compliance; Intervention; Medication; Motivational interviewing; Osteoporosis; Persistence; Systematic review

Indexed keywords

ALENDRONIC ACID; CALCIUM; IBANDRONIC ACID; RISEDRONIC ACID; VITAMIN D;

CINAHL; CLINICAL TRIAL; COCHRANE LIBRARY; EFFECT SIZE; EMBASE; HUMAN; MEDLINE; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT COUNSELING; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TELEMEDICINE;

BONE DENSITY CONSERVATION AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; MEDICATION ADHERENCE; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 71849111686     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-009-0976-0     Document Type: Review

References (36)

1. National Osteoporosis Foundation, America's bone health: the state of osteoporosis and low bone mass in our nation. Available at http://nof.org/ advocacy/prevalence/index.htm, accessed 12/15/2008. 2008.
2. United Nations, D.o.E.a.S.A., Population and Division, World Population Prospects: The 2006 Revision, Highlights, Working Paper No. ESA/P/WP.202. 2007.
3. R Burge, et al. 2007 Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025 J Bone Miner Res 22 3 465 475 10.1359/jbmr.061113 17144789 (Pubitemid 46797130)
4. Z Cole E Dennison C Cooper 2008 Update on the treatment of post-menopausal osteoporosis Br Med Bull 86 129 143 10.1093/bmb/ldn017 1:CAS:528:DC%2BD1cXmvFSkur0%3D 18477578 (Pubitemid 351809634)
5. RD Chapurlat PD Delmas 2006 Drug insight: bisphosphonates for postmenopausal osteoporosis Nat Clin Pract Endocrinol Metab 2 4 211 219 10.1038/ncpendmet0121 1:CAS:528:DC%2BD28XksFSrtLY%3D 16932286 quiz following 238
6. SR Cummings, et al. 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial Jama 280 24 2077 2082 10.1001/jama.280.24.2077 1:CAS:528:DyaK1MXjsVWruw%3D%3D 9875874 (Pubitemid 29014065)
7. DM Black, et al. 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 348 9041 1535 1541 10.1016/S0140-6736(96)07088-2 1:CAS:528:DyaK2sXisFCktQ%3D%3D 8950879 (Pubitemid 26411651)
8. ST Harris, et al. 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group Jama 282 14 1344 1352 10.1001/jama.282.14.1344 1:CAS:528:DyaK1MXmvFansr0%3D 10527181 (Pubitemid 29483192)
9. J Reginster, et al. 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group Osteoporos Int 11 1 83 91 10.1007/s001980050010 1:CAS:528:DC%2BD3cXhvFGgsr0%3D 10663363 (Pubitemid 30099515)
10. IC Chesnut, et al. 2004 Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 19 8 1241 1249 10.1359/JBMR.040325 1:CAS:528:DC%2BD2cXntFGqurw%3D (Pubitemid 41094364)
11. A Cranney, et al. 2002 Meta-analyses of therapies for postmenopausal osteoporosis IX: summary of meta-analyses of therapies for postmenopausal osteoporosis Endocr Rev 23 4 570 578 10.1210/er.2001-9002 1:CAS:528: DC%2BD38Xnt1Whs78%3D 12202472 (Pubitemid 34925651)
12. P Kothawala, et al. 2007 Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis Mayo Clin Proc 82 12 1493 1501 10.4065/82.12.1493 18053457
13. Haynes RB et al (2008) Interventions for enhancing medication adherence. Cochrane Database Syst Rev (2):CD000011
14. SM Cadarette, et al. 2007 Psychometric properties of the "Osteoporosis and You" questionnaire: osteoporosis knowledge deficits among older community-dwelling women Osteoporos Int 18 7 981 989 10.1007/s00198-007-0326-z 1:STN:280:DC%2BD2svivFaisQ%3D%3D 17333452 (Pubitemid 46889555)
15. P Werner 2005 Knowledge about osteoporosis: assessment, correlates and outcomes Osteoporos Int 16 2 115 127 10.1007/s00198-004-1750-y 15517187 (Pubitemid 40193197)
16. L Giangregorio, et al. 2008 Do patients perceive a link between a fragility fracture and osteoporosis? BMC Musculoskelet Disord 9 38 10.1186/1471-2474-9-38 18366716 (Pubitemid 351596379)
17. JA Cramer, et al. 2008 Medication compliance and persistence: terminology and definitions Value Health 11 1 44 47 18237359
18. AR Jadad, et al. 1996 Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1 1 12 10.1016/0197-2456(95)00134-4 1:STN:280:DyaK28zgvVCmug%3D%3D 8721797 (Pubitemid 26120810)
19. D Moher, et al. 1995 Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists Control Clin Trials 16 1 62 73 10.1016/0197-2456(94)00031-W 1:STN:280:DyaK2M3mt1CisQ%3D%3D 7743790
20. Cohen J (1987) Statistical power analysis for the behavioral sciences. L Erlbaum Associates, Hillsdale, NJ
21. MT Cuddihy, et al. 2004 A prospective clinical practice intervention to improve osteoporosis management following distal forearm fracture Osteoporos Int 15 9 695 700 10.1007/s00198-004-1597-2 15007544 (Pubitemid 39222651)
22. SR Majumdar, et al. 2007 Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial Osteoporos Int 18 3 261 270 10.1007/s00198-006-0248-1 1:STN:280:DC%2BD2s%2FoslOltQ%3D%3D 17086470 (Pubitemid 46233171)
23. Shu ASM, Polinski J, Jan S, Patel M, Truppo C, Breiner C, Chen Y, Weiss T, Solomon DH (2009) Adherence to Osteoporosis Medications After Patient and Physician Education: A Post-Hoc Analysis of a Randomized Controlled Trial. American Journal of Managed Care (in press)
24. A Cooper J Drake E Brankin 2006 Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study Int J Clin Pract 60 8 896 905 10.1111/j.1742-1241.2006.01059.x 1:CAS:528:DC%2BD28XpvVemsLg%3D 16800837 (Pubitemid 44082279)
25. PD Delmas, et al. 2007 Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis J Clin Endocrinol Metab 92 4 1296 1304 10.1210/jc.2006-1526 1:CAS:528: DC%2BD2sXksVSrsbc%3D 17244788 (Pubitemid 46556401)
26. M Guilera, et al. 2006 Does an educational leaflet improve self-reported adherence to therapy in osteoporosis? The OPTIMA study Osteoporos Int 17 5 664 671 10.1007/s00198-005-0031-8 1:STN:280:DC%2BD28zotlGntw%3D%3D 16437191
27. PF Cook S Emiliozzi MM McCabe 2007 Telephone counseling to improve osteoporosis treatment adherence: an effectiveness study in community practice settings Am J Med Qual 22 6 445 456 10.1177/1062860607307990 18006425
28. JT Schousboe, et al. 2005 Education and phone follow-up in postmenopausal women at risk for osteoporosis: effects on calcium intake, exercise frequency, and medication use Dis Manag Health Outcomes 13 6 395 404 10.2165/00115677- 200513060-00004 (Pubitemid 41783777)
29. JA Clowes NFA Peel R Eastell 2004 The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial J Clin Endocrinol Metab 89 3 1117 1123 10.1210/jc.2003-030501 1:CAS:528:DC%2BD2cXisVWrtbo%3D 15001596 (Pubitemid 38368399)
30. M Rossini, et al. 2006 Determinants of adherence to osteoporosis treatment in clinical practice Osteoporos Int 17 6 914 921 10.1007/s00198-006- 0073-6 1:STN:280:DC%2BD283osVKltg%3D%3D 16538553 (Pubitemid 43781506)
31. R Balkrishnan 1998 Predictors of medication adherence in the elderly Clin Ther 20 4 764 771 10.1016/S0149-2918(98)80139-2 1:STN:280:DyaK1cvgslymsQ%3D%3D 9737835 (Pubitemid 28421497)
32. S Rollnick W Miller 1995 What is motivational interviewing? Behav Cogn Psychother 23 325 334 10.1017/S135246580001643X
33. C DiIorio, et al. 2008 Using motivational interviewing to promote adherence to antiretroviral medications: a randomized controlled study AIDS Care 20 3 273 283 10.1080/09540120701593489 1:STN:280:DC%2BD1c7ptlyqsw%3D%3D 18351473
34. CE Golin, et al. 2006 A 2-arm, randomized, controlled trial of a motivational interviewing-based intervention to improve adherence to antiretroviral therapy (ART) among patients failing or initiating ART J Acquir Immune Defic Syndr 42 1 42 51 10.1097/01.qai.0000219771.97303.0a 16763491 (Pubitemid 43947945)
35. KB Schmaling 2001 A randomised controlled pilot study of motivational interviewing to change attitudes about adherence to medications for asthma J Clin Psychol Med Settings 8 3 167 172 10.1023/A:1011365519345 (Pubitemid 32842698)
36. G Ogedegbe, et al. 2008 A practice-based trial of motivational interviewing and adherence in hypertensive African Americans Am J Hypertens 21 10 1137 1143 10.1038/ajh.2008.240 18654123